Life sciences companies are using AI to speed up drug discovery, accelerate commercialization timelines, and improve back-office functions. The strong AI market in the U.S. has allowed for collaborations between AI-focused tech companies, life sciences companies, and universities. However, limitations around centralized data availability have made for challenges with deploying technology for clinical and commercial purposes. Europe has unique advantages due to many countries having centralized health data stores, collaborative networks, and strong public funding for research. As we have seen increased investment for companies utilizing AI to improve patient outcomes, life sciences companies who can unlock cross-border collaborations in the AI space may have an edge to tap into capital markets.

As AI moves from early testing to everyday business use, companies on both sides of the Atlantic are facing major changes in how work is organized, managed, and carried out. Our panel brings together experts from Europe and the United States to explain the real challenges and opportunities that come with this shift.

Hosted by Noerr | Join us for an insightful webinar exploring the practical challenges and opportunities arising from the implementation of DORA and NIS2. Whether you are advising financial institutions navigating DORA compliance, helping essential or important entities understand their NIS2 obligations, or seeking clarity on where the two regimes overlap - this webinar brings together leading legal practitioners from across Europe to share their expertise and insights.